These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 38830895)
1. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study. Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895 [TBL] [Abstract][Full Text] [Related]
2. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). Takahashi N; Hara H; Nagashima K; Hirata K; Masuishi T; Matsumoto T; Kawakami H; Yamazaki K; Hironaka S; Boku N; Muro K BMC Cancer; 2023 Aug; 23(1):726. PubMed ID: 37543568 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515 [TBL] [Abstract][Full Text] [Related]
4. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242 [TBL] [Abstract][Full Text] [Related]
5. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer. Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718 [TBL] [Abstract][Full Text] [Related]
6. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864 [TBL] [Abstract][Full Text] [Related]
8. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215 [TBL] [Abstract][Full Text] [Related]
9. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932 [TBL] [Abstract][Full Text] [Related]
10. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856 [TBL] [Abstract][Full Text] [Related]
11. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial. Botsen D; Chabaud S; Perrier H; Ammarguellat H; Jestin-Le-Tallec V; Olesinski J; Toullec C; Aparicio T; Ben Abdelghani M; Borg C; Bouche O; Coutzac C; Devaud H; Di Fiore F; Dubreuil O; Evesque L; Huguenin B; Muller M; Poureau PG; Oularue E; Tougeron D; Zaanan A; Ammari S; De Sousa Carvalho N; Decazes P; De La Fouchardiere C Dig Liver Dis; 2024 Aug; 56(8):1281-1287. PubMed ID: 38762353 [TBL] [Abstract][Full Text] [Related]
12. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174 [TBL] [Abstract][Full Text] [Related]
13. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008 [No Abstract] [Full Text] [Related]
14. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. Ilson DH; Tabernero J; Prokharau A; Arkenau HT; Ghidini M; Fujitani K; Van Cutsem E; Thuss-Patience P; Beretta GD; Mansoor W; Zhavrid E; Alsina M; George B; Catenacci D; McGuigan S; Makris L; Doi T; Shitara K JAMA Oncol; 2020 Jan; 6(1):e193531. PubMed ID: 31600365 [TBL] [Abstract][Full Text] [Related]
16. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675 [TBL] [Abstract][Full Text] [Related]
17. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741 [TBL] [Abstract][Full Text] [Related]
18. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986 [TBL] [Abstract][Full Text] [Related]
19. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Hayashi K; Furuta M; Furusawa K; Hamaguchi T; Watanabe M; Inokuchi Y; Onuma S; Hashimoto I; Suematsu H; Nagasawa S; Kanematsu K; Yamada T; Notsu A; Ogata T; Oshima T; Machida N; Furuse J; Maeda S Anticancer Res; 2023 Jun; 43(6):2831-2840. PubMed ID: 37247885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]